Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 7/24/13 → 6/30/15 |
Funding
- Quintiles Inc: $27,024.00
A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A.
- Radulescu, Vlad (PI)